این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Middle East Journal of Cancer، جلد ۱۶، شماره ۴، صفحات ۲۹۹-۳۲۱
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region
چکیده انگلیسی مقاله Approximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC. For metastatic BC (mBC), standard therapy options include targeted approaches, such as cyclin-dependent kinase 4/6 inhibitors, phosphoinositide 3-kinase inhibitors, poly (adenosine diphosphate-ribose) polymerase inhibitors, and anti-programmed death-ligand 1 agents, depending on tumor type and its molecular profile. Recent clinical trials reported significant clinical benefits from novel anti‑HER2 antibody‑drug conjugates, such as trastuzumab deruxtecan in HER2‑low mBC. Novel treatment options have increased the complexity of the clinical decision‑making process, particularly for treatment sequencing for each clinical setting. A regional expert committee meeting was held to discuss the challenges, overcome limitations, and present recommendations to enhance HER2 reporting as well as treatment of patients with HER2‑low mBC in the Middle East and Africa region.
کلیدواژه‌های انگلیسی مقاله Breast neoplasms,HER2-low,Immunoconjugates,Trastuzumab deruxtecan,Sacituzumab govitecan
نویسندگان مقاله Shaheenah Dawood |
Department of Oncology, Mediclinic Hospital, Dubai, United Arab Emirates

Mohsen Mokhtar |
Department of Oncology, Cairo University, Cairo, Egypt

Ahmed Alwbari |
Department of Oncology, Almoosa Specialist Hospital, Oncology Center, Al Mubarraz, Saudi Arabia

Bernardo Leon Rapoport |
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

Ece Esin |
Department of Medical Oncology, Bayindir Hospital, Ankara, Turkey

Hassan Jaafar |
Department of Oncology, Sheikh Khalifa Specialty Hospital, Abu Dhabi, United Arab Emirates

Jamal Zekri |
Department of Oncology, Royal Preston Hospital, Sharoe Green Lane, Fulwood, Preston, United Kingdom

Narjiss Berrada |
Department of Oncology, Chellah University, Rabat, Morocco

Ozgur Ozyilkan |
Department of Oncology, Baskent University, Ankara, Turkey

Nagi S. El Saghir |
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

نشانی اینترنتی https://mejc.sums.ac.ir/article_50590_31ce17421f15ccce87c42b6fa6221037.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات